Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director · SEE REMARKS | June 27, 2023 | June 28, 2023 |
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Director | June 10, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 27, 2023 · Filed June 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 671,423 |
Reported balance
After 2023-06-27 transaction · row 1
1 source rowRow 1 · 2023-06-27 · Sale · Disposed 25,000 · Balance 671,423 F1: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of December 29, 2022. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 23,090 |
Reported balance
Holding disclosure · report date 2023-06-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 23,090 F2: Shares held by wife. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 104,449 |
Reported balance
Holding disclosure · report date 2023-06-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 104,449 F3: Shares held by David M. Epstein 2019 Trust For Elle. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Elle and may be deemed to beneficially own these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 104,449 |
Reported balance
Holding disclosure · report date 2023-06-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 104,449 F4: Shares held by David M. Epstein 2019 Trust For Zoe. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Zoe and may be deemed to beneficially own these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,579 |
Reported balance
Holding disclosure · report date 2023-06-27 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 16,579 F5: Shares held by David M. Epstein 2019 Trust For Robert. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Robert and may be deemed to beneficially own these securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,579 |
Reported balance
Holding disclosure · report date 2023-06-27 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 16,579 F6: Shares held by David M. Epstein 2019 Trust For Shelley. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Shelley and may be deemed to beneficially own these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of December 29, 2022.
F2: Shares held by wife.
F3: Shares held by David M. Epstein 2019 Trust For Elle. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Elle and may be deemed to beneficially own these securities.
F4: Shares held by David M. Epstein 2019 Trust For Zoe. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Zoe and may be deemed to beneficially own these securities.
F5: Shares held by David M. Epstein 2019 Trust For Robert. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Robert and may be deemed to beneficially own these securities.
F6: Shares held by David M. Epstein 2019 Trust For Shelley. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Shelley and may be deemed to beneficially own these securities.
GYRE THERAPEUTICS, INC.
Report date June 10, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.95 · Expires 2036-06-10 | Direct | 40,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 40,000 · Balance 40,000 F1: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 30, 2026 22:17 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001140361-26-027007 · form4.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:22 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001140361-25-021792 · form4.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 14, 2024 Filed Aug 17, 2024 01:07 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001140361-24-037713 · form4.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2034-08-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 52,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 14, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 06, 2024 Filed Aug 8, 2024 20:31 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 1,866 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0001140361-24-036417 · form4.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,866 Underlying: Common Stock · 1,866 shares Expires 2034-08-06 F1 · derivative.exercise_date: These options vest as to one-third on each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 27, 2023 Filed Jun 28, 2023 20:02 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 25,000 | $6.70 | $167,500.00 |
DisclosureSEC source: 0001415889-23-010388 · form4-06282023_080616.xml · nonDerivative · entry 1 Epstein David M. · CIK 0001488668 · Director · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 671,423 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of December 29, 2022. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:10 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 420,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022387 · tm236831-3_4seq1.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:19 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001415889-22-001517 · form4-02172022_010237.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:46 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $28.69 | $0.00 |
DisclosureSEC source: 0000899243-21-007431 · doc4.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:21 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0000899243-21-000741 · doc4.xml · derivative · entry 9 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,116 Underlying: Common Stock · 3,000 shares Expires 2029-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:21 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 2,015 | $31.80 | $64,074.78 |
DisclosureSEC source: 0000899243-21-000741 · doc4.xml · nonDerivative · entry 3 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,423 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.55 to $32.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:21 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 9,985 | $30.99 | $309,430.16 |
DisclosureSEC source: 0000899243-21-000741 · doc4.xml · nonDerivative · entry 2 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,438 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.55 to $31.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 23:21 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $6.42 | $19,260.00 |
DisclosureSEC source: 0000899243-21-000741 · doc4.xml · nonDerivative · entry 1 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 708,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 00:39 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0000899243-20-034186 · doc4.xml · derivative · entry 7 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,116 Underlying: Common Stock · 2,500 shares Expires 2029-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 00:39 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 2,500 | $6.42 | $16,050.00 |
DisclosureSEC source: 0000899243-20-034186 · doc4.xml · nonDerivative · entry 1 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:17 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0000899243-20-032670 · doc4.xml · derivative · entry 9 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,616 Underlying: Common Stock · 3,000 shares Expires 2029-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:17 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 1,077 | $33.45 | $36,020.80 |
DisclosureSEC source: 0000899243-20-032670 · doc4.xml · nonDerivative · entry 3 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,923 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $33.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:17 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 10,923 | $32.64 | $356,552.94 |
DisclosureSEC source: 0000899243-20-032670 · doc4.xml · nonDerivative · entry 2 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,000 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.19 to $33.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:17 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $6.42 | $19,260.00 |
DisclosureSEC source: 0000899243-20-032670 · doc4.xml · nonDerivative · entry 1 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0000899243-20-030313 · doc4.xml · derivative · entry 9 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,616 Underlying: Common Stock · 3,000 shares Expires 2029-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 83 | $31.88 | $2,645.63 |
DisclosureSEC source: 0000899243-20-030313 · doc4.xml · nonDerivative · entry 3 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 711,923 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 11,917 | $31.13 | $371,010.77 |
DisclosureSEC source: 0000899243-20-030313 · doc4.xml · nonDerivative · entry 2 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 712,006 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.74 to $31.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:56 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $6.42 | $19,260.00 |
DisclosureSEC source: 0000899243-20-030313 · doc4.xml · nonDerivative · entry 1 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 21:07 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.42 | $0.00 |
DisclosureSEC source: 0000899243-20-026891 · doc4.xml · derivative · entry 8 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,616 Underlying: Common Stock · 3,000 shares Expires 2029-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 21:07 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | SaleCommon Stock | 12,000 | $30.33 | $363,962.40 |
DisclosureSEC source: 0000899243-20-026891 · doc4.xml · nonDerivative · entry 2 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,923 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.10 to $30.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2020 Filed Oct 2, 2020 21:07 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | Exercise / conversionCommon Stock | 3,000 | $6.42 | $19,260.00 |
DisclosureSEC source: 0000899243-20-026891 · doc4.xml · nonDerivative · entry 1 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 732,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries B Preferred Stock · Derivative | 13,136 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003358 · doc4.xml · derivative · entry 6 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F3 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F3 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. F3 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries A Preferred Stock · Derivative | 69,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003358 · doc4.xml · derivative · entry 5 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 23,090 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by wife. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionSeries A Preferred Stock · Derivative | 732,560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003358 · doc4.xml · derivative · entry 4 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 242,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 4,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003358 · doc4.xml · nonDerivative · entry 3 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series B Preferred Stock had no expiration date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 23,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003358 · doc4.xml · nonDerivative · entry 2 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by wife. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:57 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | ConversionCommon Stock | 242,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003358 · doc4.xml · nonDerivative · entry 1 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, all shares of Series A Preferred Stock automatically converted into shares of Common Stock of the Issuer on a one-for-3.01581 basis. The Series A Preferred Stock had no expiration date. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:51 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 278,532 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-002442 · doc4.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,532 Underlying: Common Stock · 278,532 shares Expires 2030-01-29 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.